Mathias holds a master’s in engineering in Molecular Biotechnology from Uppsala University and Ph.D. in molecular biology from Karolinska Institutet. He is a co-founder of the cord blood bank Cellaviva, established in 2014, a company that has evolved to NextCell Pharma AB which is developing stem cell-based therapies for autoimmune diseases. Currently, NextCell has two ongoing clinical trials in type-1 diabetes.
There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.